These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6127373)

  • 1. Dopamine metabolism increases in post-mortem schizophrenic basal ganglia.
    Toru M; Nishikawa T; Mataga N; Takashima M
    J Neural Transm; 1982; 54(3-4):181-91. PubMed ID: 6127373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies.
    Langlais PJ; Thal L; Hansen L; Galasko D; Alford M; Masliah E
    Neurology; 1993 Oct; 43(10):1927-34. PubMed ID: 8105420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains.
    Noga JT; Hyde TM; Herman MM; Spurney CF; Bigelow LB; Weinberger DR; Kleinman JE
    Synapse; 1997 Nov; 27(3):168-76. PubMed ID: 9329152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients.
    Toru M; Watanabe S; Shibuya H; Nishikawa T; Noda K; Mitsushio H; Ichikawa H; Kurumaji A; Takashima M; Mataga N
    Acta Psychiatr Scand; 1988 Aug; 78(2):121-37. PubMed ID: 2906213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine and noradrenaline in post-mortem brain in Huntington's disease and schizophrenic illness.
    Bird ED; Spokes EG; Iversen LL
    Acta Psychiatr Scand Suppl; 1980; 280():63-73. PubMed ID: 6447433
    [No Abstract]   [Full Text] [Related]  

  • 6. 123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia.
    Sjøholm H; Bratlid T; Sundsfjord J
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):27-31. PubMed ID: 14712338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical and structural changes in the brain in patients with movement disorder.
    Cross AJ; Crow TJ; Ferrier IN; Johnson JA; Johnstone EC; Owen F; Owens DG; Poulter M
    Psychopharmacology Suppl; 1985; 2():104-10. PubMed ID: 2860653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G-proteins (Gi, Go) in the basal ganglia of control and schizophrenic brain.
    Okada F; Crow TJ; Roberts GW
    J Neural Transm Gen Sect; 1990; 79(3):227-34. PubMed ID: 2105097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine mechanisms in chronic schizophrenia: post-mortem neurochemical findings.
    Crow TJ; Baker HF; Cross AJ; Joseph MH; Lofthouse R; Longden A; Owen F; Riley GJ; Glover V; Killpack WS
    Br J Psychiatry; 1979 Mar; 134():249-56. PubMed ID: 41609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic drug action in schizophrenic patients: effect on cortical dopamine metabolism after long-term treatment.
    Bacopoulos NC; Spokes EG; Bird ED; Roth RH
    Science; 1979 Sep; 205(4413):1405-7. PubMed ID: 38504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bimodal distribution of dopamine receptor densities in brains of schizophrenics.
    Seeman P; Ulpian C; Bergeron C; Riederer P; Jellinger K; Gabriel E; Reynolds GP; Tourtellotte WW
    Science; 1984 Aug; 225(4663):728-31. PubMed ID: 6147018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Physiopathologic chemistry of the schizophrenic brain].
    Shohmori T; Morimasa T
    Nihon Rinsho; 1987 Sep; 45(9):2105-13. PubMed ID: 2892954
    [No Abstract]   [Full Text] [Related]  

  • 13. Difficulties in comparing catecholamine-related enzymes from the brains of schizophrenics and controls.
    Wyatt RJ; Erdelyi E; Schwartz M; Herman M; Barchas JD
    Biol Psychiatry; 1978 Jun; 13(3):317-34. PubMed ID: 27253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia.
    Bird ED; Spokes EG; Iversen LL
    Brain; 1979 Jun; 102(2):347-60. PubMed ID: 455044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced dopamine turnover in the basal ganglia of depressed suicides.
    Bowden C; Cheetham SC; Lowther S; Katona CL; Crompton MR; Horton RW
    Brain Res; 1997 Sep; 769(1):135-40. PubMed ID: 9374281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biochemical analysis of dopaminergic nerve terminals of post-mortem brain from schizophrenic patients (author's transl)].
    Toru M; Shibuya H; Nishikawa T; Semba J; Mataga N; Takashima M
    Seishin Shinkeigaku Zasshi; 1981; 83(7):430-47. PubMed ID: 7330112
    [No Abstract]   [Full Text] [Related]  

  • 17. Studies in postmortem dopamine uptake. II. Alterations of the synaptosomal catecholamine uptake in postmortem brain regions in schizophrenia.
    Haberland N; Hetey L
    J Neural Transm; 1987; 68(3-4):303-13. PubMed ID: 3559542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia.
    Bird ED; Iversen LL
    Brain; 1974 Sep; 97(3):457-72. PubMed ID: 4157009
    [No Abstract]   [Full Text] [Related]  

  • 19. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
    Farde L; Wiesel FA; Stone-Elander S; Halldin C; Nordström AL; Hall H; Sedvall G
    Arch Gen Psychiatry; 1990 Mar; 47(3):213-9. PubMed ID: 1968328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased brain dopamine and dopamine receptors in schizophrenia.
    Mackay AV; Iversen LL; Rossor M; Spokes E; Bird E; Arregui A; Creese I; Synder SH
    Arch Gen Psychiatry; 1982 Sep; 39(9):991-7. PubMed ID: 7115016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.